Precede Biosciences Presents New Data at ESMO 2024 Demonstrating Ability to Reveal Tumor PSMA Expression from a Simple Blood Test that is Highly Correlated with PSMA-PET Imaging
Article Content
- Prostate-specific membrane antigen (PSMA) is a leading target for next-generation prostate cancer therapies, with one FDA-approved drug and 30 in development.
- Quantitative PSMA-PET imaging is required to determine patient eligibility for the first FDA-approved PSMA-targeted drug and is an inclusion criterion for ongoing trials.
BOSTON, Sept. 15, 2024 (GLOBE NEWSWIRE) — Pressed Biosciences, a company impacting the development and use of precision medicines through its comprehensive, first-in-class liquid biopsy platform, today shared the company’s scientific poster presentation from the 2024 European Society for Medical Oncology Annual Meeting, taking place September 13-17, 2024 in Barcelona, Spain.
Article Content
“These data highlight the potential of comprehensive genomic profiling to provide a non-invasive, clinically accessible alternative to tumor PSMA expression in men with metastatic castration-resistant prostate cancer,” said Jacob E. Pershock, MD, assistant professor in the Department of Hematology and Medical Oncology at the Winship Cancer Institute of Emory University. “Because PSMA-PET is not equitably available throughout the United States and around the world, assessing tumor PSMA expression from blood could enable optimal patient identification for approved and many emerging PSMA-targeted drugs.”
“These promising data highlight the potential of the Precede Bio platform to solve important targets with a simple blood draw,” said Carl Barrett, Chief Science Officer at Precede Bio. “PSMA is the first target for the next wave of precision medicine for prostate cancer, and these data support the promise of our platform to inform treatment selection in this context. We look forward to continuing to work with academics and leading drug developers to advance this important work, while continuing our work on other high-value targets, such as DLL3 and STEAP1, all with the goal of informing treatment selection of drugs against these targets from the same 1 mL of plasma.”
Article Content
Data presented at the ESMO Annual Meeting 2024 can be found at Presentations Section of Company website Below:
About Precede Biosciences
Precede Biosciences is breaking the barriers to precision medicine by redefining what can be learned from a simple blood draw. By understanding the fundamental biology behind a disease at any given moment, researchers and clinicians can better target drugs to the right patients in both drug development and clinical practice. Precede Bio seeks to improve drug development success rates and be part of building a future where every patient has access to rapid, non-invasive diagnosis and treatment that is accurate for the biology of their disease. The Precede Bio platform is available to drug developers and academic researchers. To learn more, visit www.precede.bio Or follow us on X/Twitter and LinkedIn.
Media Contacts:
Donnell M. Gregory
Media@precede.bio
Adam Silverstein
adam@scientpr.com
Share this article on your social network
Comments are closed, but trackbacks and pingbacks are open.